Latest research on Simponi

Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.

Latest findings

Biologic disease-modifying antirheumatic drugs (bDMARDs), also known as biologics, cover TNF inhibitors (TNFi) (adalimumab (ADA) (Humira, AbbVie Ltd.), certolizumab pegol (CER) (Cimzia, UCB Pharma SA), etanercept (ETN) (Enbrel, Pfizer Ltd.), golimumab (GOL) (Simponi, Janssen Biologics B.V), infliximab (IFX) (Remicade, Janssen Biologics B.V.)) and agents based on other mechanisms of action (abatacept (ABT) (Orencia, Bristol-Myers Squibb Pharma EEIG), anakinra (ANA) (Kineret, Biovitrum AB), rituximab (RTX) (MabThera, Roche Registration Ltd) and tocilizumab (TOC) (RoActemra, Roche Registration Ltd. [source, 2015]
Infliximab (Remicade), Adalimumab (Humira) and Golimumab (Simponi) are humanized monoclonal anti-TNF antibodies. [source, 2015]
The manufacturers of the TNF-α inhibitor golimumab (Simponi) submitted a cost-effectiveness analysis of the product in the treatment for ankylosing spondylitis to the National Institute for Health and Clinical Excellence in November 2010 [23]. [source, 2014]
(golimumab or Simponi or CNTO 148).ti,ab. [source, 2014]
#7. golimumab or Simponi or CNTO 148 [source, 2014]
Golimumab (GLM) (trade name Simponi), a fully human anti-TNF-α monoclonal antibody, was approved by the US Food and Drug Administration in 2009 for the use with methotrexate (MTX) in adults with moderate-to-severe active rheumatoid arthritis (RA) and with or without MTX or other biologic disease-modifying antirheumatic drugs in adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS) [9]. [source, 2014]
The drugs mined were T: etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia) and golimumab (Simponi); C: dexamethasone, Decadron, methylprednisolone, Medrol, solu-Medrol prednisolone, Prednisone and deltasone; M: methotrexate, Mtx, Rheumatrex and Trexall. [source, 2013]
More recent efforts to discover new target therapies have achieved some success in alleviating inflammation; for instance, TNF-α blockers, like the monoclonal antibodies etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia) and golimumab (Simponi), and B-Lymphocyte depleting therapies, like rituximab (Rituxan), have benefited many RA patients [2,3]. [source, 2013]
Only two of the top 25 consumer-promoted products, etanercept (Enbrel) and golimumab (Simponi), were biologic therapies, whereas biologics accounted for 9 of the 25 top-selling products. [source, 2013]